SAGIMET BIOSCIENCES INC-A (SGMT) Stock Price, Quote, News and Overview
NASDAQ:SGMT - Nasdaq - US7867001049 - Common Stock - Currency: USD
SGMT Quote, Performance and Key Statistics
3.31
+0.16 (+5.08%)
The current stock price of SGMT is 3.31 USD. In the past month the price decreased by -10.78%. In the past year, price decreased by -23.38%.
SGMT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.73 | 340.25B | ||
| AMGN | AMGEN INC | 14.28 | 152.20B | ||
| GILD | GILEAD SCIENCES INC | 13.74 | 132.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1712.03 | 127.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.38 | 66.78B | ||
| ARGX | ARGENX SE - ADR | 326.83 | 37.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
| NTRA | NATERA INC | N/A | 20.68B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.78B | ||
| BIIB | BIOGEN INC | 7.23 | 17.44B |
Related stock screener links
About SGMT
Company Profile
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 14 full-time employees. The company went IPO on 2023-07-14. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
Company Info
SAGIMET BIOSCIENCES INC-A
155 Bovet Rd., Suite 303
San Mateo CALIFORNIA US
Employees: 14
Company Website: https://sagimet.com/
Investor Relations: https://ir.sagimet.com/
Phone: 16505618600
SAGIMET BIOSCIENCES INC-A / SGMT FAQ
What is the stock price of SAGIMET BIOSCIENCES INC-A today?
The current stock price of SGMT is 3.31 USD. The price increased by 5.08% in the last trading session.
What is the ticker symbol for SAGIMET BIOSCIENCES INC-A stock?
The exchange symbol of SAGIMET BIOSCIENCES INC-A is SGMT and it is listed on the Nasdaq exchange.
On which exchange is SGMT stock listed?
SGMT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SAGIMET BIOSCIENCES INC-A stock?
15 analysts have analysed SGMT and the average price target is 31.77 USD. This implies a price increase of 859.69% is expected in the next year compared to the current price of 3.31. Check the SAGIMET BIOSCIENCES INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SAGIMET BIOSCIENCES INC-A worth?
SAGIMET BIOSCIENCES INC-A (SGMT) has a market capitalization of 106.58M USD. This makes SGMT a Micro Cap stock.
How many employees does SAGIMET BIOSCIENCES INC-A have?
SAGIMET BIOSCIENCES INC-A (SGMT) currently has 14 employees.
What are the support and resistance levels for SAGIMET BIOSCIENCES INC-A (SGMT) stock?
SAGIMET BIOSCIENCES INC-A (SGMT) has a support level at 3.3 and a resistance level at 3.32. Check the full technical report for a detailed analysis of SGMT support and resistance levels.
Should I buy SAGIMET BIOSCIENCES INC-A (SGMT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGMT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGMT, evaluating the profitability, health, valuation and growth aspects
- SAGIMET BIOSCIENCES INC-A (SGMT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SAGIMET BIOSCIENCES INC-A (SGMT) Sales and EPS estimates to see what analysts future expectations are.
- SAGIMET BIOSCIENCES INC-A (SGMT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SAGIMET BIOSCIENCES INC-A (SGMT) Insider and Institutional Ownership to learn about the owners and their transactions.
- SAGIMET BIOSCIENCES INC-A (SGMT) Stock Chart to make your own analysis
- SAGIMET BIOSCIENCES INC-A (SGMT) Latest news and press-releases to stay up to date.
Does SAGIMET BIOSCIENCES INC-A (SGMT) stock pay dividends?
SGMT does not pay a dividend.
When does SAGIMET BIOSCIENCES INC-A (SGMT) report earnings?
SAGIMET BIOSCIENCES INC-A (SGMT) will report earnings on 2025-05-14, before the market open.
What is the Price/Earnings (PE) ratio of SAGIMET BIOSCIENCES INC-A (SGMT)?
SAGIMET BIOSCIENCES INC-A (SGMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
What is the Short Interest ratio of SAGIMET BIOSCIENCES INC-A (SGMT) stock?
The outstanding short interest for SAGIMET BIOSCIENCES INC-A (SGMT) is 14.62% of its float. Check the ownership tab for more information on the SGMT short interest.
SGMT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SGMT. When comparing the yearly performance of all stocks, SGMT is a bad performer in the overall market: 80.47% of all stocks are doing better.
SGMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGMT. No worries on liquidiy or solvency for SGMT as it has an excellent financial health rating, but there are worries on the profitability.
SGMT Financial Highlights
Over the last trailing twelve months SGMT reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 45.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.43% | ||
| ROE | -29.25% | ||
| Debt/Equity | 0 |
SGMT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SGMT. The Buy consensus is the average rating of analysts ratings from 15 analysts.